Aeterna Zentaris to Announce First Quarter 2018 Financial and Operating Results on May 7, 2018
May 01 2018 - 5:05PM
Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS)
will announce its first quarter 2018 financial and operating
results after market close on Monday, May 7, 2018. The Company will
host a conference call to discuss these results on Tuesday, May 8,
2018 at 8:30 a.m. Eastern Time.
Participants may access the conference call by telephone using
the following numbers:
- Toll-Free: 877-407-8029, Confirmation #13679691
- Toll: 201-689-8029, Confirmation #13679691
A replay will also be available on the Company’s website for a
period of 30 days.
About Aeterna Zentaris Inc.
Aeterna Zentaris Inc. is a specialty biopharmaceutical company
focused on developing and commercializing, principally through
out-licensing arrangements, Macrilen™ (macimorelin), an orally
available ghrelin agonist, to be used in the diagnosis of patients
with adult growth hormone deficiency. Aeterna Zentaris has
entered into a license and assignment agreement with a wholly-owned
subsidiary of Strongbridge Biopharma plc to carry out development,
manufacturing, registration and commercialization of Macrilen™
(macimorelin) in the United States and Canada. For more
information, visit www.aezsinc.com.
Contact:
Aeterna Zentaris Inc.James ClavijoChief Financial
OfficerIR@aezsinc.com843-900-3201
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Jul 2023 to Jul 2024